Table 3. Baseline characteristics of the 72 PPGL patients according to the occurrence of metastasis by PHEO or PGL.

Variable	Non-metastatic PHEO (N = 50, 79.4%)	Metastatic PHEO (N = 13, 20.6%)	P	Non-metastatic PGL (N = 7, 77.8%)	Metastatic PGL (N = 2, 22.2%)	P
Age (years), mean±SD	48.8 ± 13.3	40.6 ± 17.8	0.072	40.6 ± 21.3	32.0 ± 2.8	0.606
Female, N (%)	44 (88.0%)	8 (61.5%)	0.067	3 (42.9%)	2 (100.0%)	0.530
Height (cm), mean±SD	157.0 ± 6.9	162.2 ± 7.2	0.020	165.9 ± 8.7	163.8 ± 0.4	0.746
Weight (kg), mean±SD	58.1 ±8.2	61.2 ± 9.2	0.251	68.0 ± 14.9	58.7 ± 1.8	0.428
BMI (kg/m2), mean±SD	23.6 ±3.4	23.3 ± 3.3	0.714	24.4 ± 3.7	21.9 ± 0.6	0.394
Size of tumor (cm), mean±SD	6.7 ± 3.4	8.5 ± 4.2	0.112	6.1 ± 2.6	9.0 ± 4.9	0.282
Familial form, N (%)	4 (8.0%)	2 (15.4%)	0.781	0 (0.0%)	0 (0.0%)	>0.999
Functioning type, N (%)	41 (82.0%)	13 (100.0%)	0.227	6 (85.7%)	0 (0.0%)	0.537
Adrenergic type, N (%)	30 (73.2%)	6 (46.2%)	0.143	3 (50.0%)	0 (0.0%)	>0.999
Noradrenergic type, N (%)	11 (26.8%)	7 (53.8%)		3 (50.0%)	0 (0.0%)
UMN (μg/day), median [IQR]	1099.2 [161.0; 3518.0]	1373.3 [442.3; 4333.0]	0.644	81.7 [78.9; 91.5]	14.8 [NA]	0.740
UNM (μg/day), median [IQR]	3481.5 [1682.6; 7521.4]	4000.3 [1926.5; 5281.1]	0.878	6045.7 [3510.0; 9873.2]	848.0 [NA]	0.229
Loss of SDHB staining on IHC, N (%)	4 (8.0%)	4 (30.8%)	0.084	2 (28.6%)	1 (50.0%)	0.200
Duration of follow-up (months), mean±SD	46.9 ± 37.7	32.6 ± 30.2	0.211	54.1 ± 48.2	26.5 ± 36.1	0.484

BMI, body mass index; IQR, interquartile ranges; IHC, immunohistochemistry; PHEO, pheochromocytoma; PGL, paraganglioma; PPGL, pheochromocytoma and paraganglioma; NA, not applicable; SD, standard deviation; SDHB, succinate dehydrogenase gene subunit B; UMN, urine fractionated metanephrine; UNM, urine fractionated normetanephrine.

If the UMN levels were high, with or without elevated UNM levels, the catecholamine type was adrenergic type. If the UNM levels were high, without elevated UMN levels, the catecholamine type was noradrenergic type.

Significant results (P<0.05) are in bold.